surgical procedures, but also the administration of medicines to control lipids, blood pressure, antidepressants and even hypoglycemia, and even then those expenditures does not consider the indirect expenses such as transportation and escort the patient to the hospital and absence from work. 
OBJECTIVES:
Although the Advisory Committee for Immunization Practices (ACIP) and other organizations recommend annual influenza vaccination for cardiovascular disease patients (CVD), the vaccination rate is low in this risk group. Economic assessment of vaccination will aid public officials plan campaigns to increase coverage. METHODS: We estimated using a Monte Carlo (probabilistic) spreadsheet-based decision tree, the cost-effectiveness of vaccination to prevent hospitalization and death in all 27.1 million CVD patients in the US. We then estimated the benefit-cost ratios (BCR) associated with hospitalization and death averted by increasing coverage rates by 10% in all adult CVD patients from the current rates of 45% and 65% (for ages <65 years and ≥65 years, respectively). Finally, we estimated the BCR associated with reaching the healthy people 2020 goal of vaccinating 90% of person's ≥65 years and 80% of adults' <65 years. We obtained treatment cost data from Marketscan database (2005) (2006) (2007) (2008) (2009) (2010) 
Erectile dysfunction is a common male sexual disorder worldwide. Three oral medications -sildenafil, vardenafil, and tadalafil -have been used to treat erectile dysfunction. This study aimed to conjointly evaluate the therapeutic risks and benefits of the three medications to assist decision making of prescribing from the perspective of both physicians and patients. METHODS: A decision model was created to compare the risk-benefit of the aforementioned medications. Using published meta-analysis data, we performed a probabilistic Monte Carlo simulation to estimate the joint distribution of each type of adverse event (i.e., risk; categories included: any adverse event, serious cardiovascular (CV) events, headache, flushing, and dyspepsia) and effectiveness (defined as proportion of patients with improved erections). The incremental risk-benefit ratios (ICBRs) were calculated, and the results were illustrated by incremental risk-benefit planes. To account for differential risk preferences across patients, the results were also illustrated using risk-benefit acceptability curves and netbenefit curves. RESULTS: When risk was defined as having any adverse event, serious CV event, or headache, sildenafil was dominated by vardenafil (ICBR= -1.00, -0.20, and -3.20, respectively); tadalafil showed increasing risk and benefit as compared to vardenafil (ICBR=0.83, 0.03, and 0.13, respectively). Tadalafil dominated sildenafil and vardenafil when balancing between the risk of flushing/dyspepsia and the drug efficacy. CONCLUSIONS: Based on patients' concern of various categories of adverse events and assuming negligible concern over medical costs, vardenafil or tadalafil may be preferred over sildenafil. 
PCV66 ESTIMATING COSTS SAVINGS FROM A CME ACTIVITY TO PREVENT BLEEDING-RELATED COMPLICATIONS AND TRANSFUSION

OBJECTIVES:
In 2011, investments in continuing medical education (CME) exceeded $2 billion. Few studies report the economic impact of CME activities. Greater understanding of the economic value of CME assists stakeholders and health care cost payers in resource allocation. It is not feasible to obtain patientlevel data after each CME activity. We developed a model to estimate the potential health care cost savings associated with CME activity outcomes.
METHODS:
We evaluated data from a certified CME symposium for surgeons that reviewed the Society for Thoracic Surgeons (STS) blood conservation guidelines. The activity promoted prevention of bleeding-related complications (BRCs). We estimated the potential savings of averted BRCs from the provider perspective predicted by participants' self-reported commitment to change (CTC). Model parameter estimates were from: 1) costs of BRCs in 103,826 cardiac operations; 2) costs of reoperation for bleeding in 133,001 coronary artery bypass graft surgeries; 3) operative volume from the STS workforce report. The base case was 3 in 10 participants preventing one BRC in 2% of operations over 1 year. Probabilistic sensitivity analysis (PSA) using second-order Monte Carlo simulations was used to model parameter uncertainty. Results were standardized to 2012 $US using the medical care component of the Consumer Price Index. RESULTS: 93.8% of participants (n=133) reported CTC, a validated measure of behavior change. For BRCs, the savings for the base case was $1,500,112. PSA estimated the mean savings as $1,502,769 (95% CI, $869,860-$2,359,068). For reoperation for bleeding, the savings for the base case was $2,974,497. PSA estimated the mean savings as $2,959,117 (95% CI, $1,135,992-$5,566,487). CONCLUSIONS: Plausible economic estimates suggest that CMErelated learning favorably impacting clinical practice yields substantial cost savings. Model prediction of averted costs associated with CME allows estimation of the economic impact on surgical outcomes in the absence of patient-level outcomes data related to CME activities. 
PCV67 EVALUATION OF ECONOMIC AND MEDICAL CONSEQUENCES OF THE ROTARY LEFT VENTRICULAR ASSIST DEVICE WITH A DISCHARGE AT HOME IN FRANCE
OBJECTIVES:
Advanced heart failure (HF) is a leading cause of death in developed countries with a one-year mortality rate estimated at 40% after the first hospitalization. In France, HF affects 150 000 persons with annual costs of up to 1,6 billon euros. Cardiac transplantation is the most effective treatment. However, because of a limited donor organ supply, innovative technics as left ventricular assist devices (LVAD) are developed as bridge to transplantation for over 10 years. The aim of this study is to assess the medical and economic consequences of LVAD in adults with advanced HF in France. METHODS: Between April 2008 and November 2011, 55 patients were included in this study in 14 French hospitals and were followed during one year after implantation. The primary medical outcome was the discharge at home and secondary medical outcome was the final situation of patient. This prospective economic analysis adopted the health care payer's perspective and took into account direct medical and non-medical costs. RESULTS: This intermediate analysis included 21 patients. LVAD used are HeartMate II (n=12), Jarvik 2000 (n=8) and Ventrassist (n=1). On the 21 patients, 15 were discharged at home spending an average of 265 days (8.7 months) at home. During the follow-up period, 4 patients were transplanted, 6 patients died, and 11 were still on device at home. The mean total cost per implanted patient was €161,843 (±36,533). The device and initial hospitalization are the most important costs and represent respectively 58% and 30% of the total cost. One day spent at home costs in average €59 CONCLUSIONS: Continuous-flows LVAD represent a costly strategy in the HF treatment. However, LVAD allow the patient to be discharged at home instead of awaiting heart transplantation at hospital. 
PCV68 ECONOMIC COMPARISON OF HEMOSTATIC AGENTS IN CARDIAC SURGERY
